Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
State of the Art and Perspectives in Lung Cancer Immunotherapy
share announcement

State of the Art and Perspectives in Lung Cancer Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 1697

Special Issue Editor

Dr. Elizabeth Fabre

E-Mail Website
Guest Editor
1. Department of Thoracic Oncology, Hôpital Européen Georges Pompidou, AP-HP, Carpem Cancer Institute, 75015 Paris, France
2. INSERM Team UMR_S970, Immunotherapy and Antiangiogenic Treatment in Cancerology, Paris Descartes University, 75015 Paris, France
Interests: biomarkers of resistance; immune checkpoint inhibitors; lung cancer; resident memory T cells; vaccination
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immune checkpoint inhibitors have drastically changed therapeutic strategies in lung cancer. However, novel composite and dynamic biomarkers of immune evasion are needed to develop tailored strategies. Indeed, a global approach integrating both immune and tumor-related parameters is crucial. Numerous ongoing clinical trials are evaluating novel immune-based combinations in order to overcome resistance pathways and reshape the immunotherapy landscape. However, an understanding of cellular and molecular mechanisms of resistance is essential to guide personalized immunotherapies.

This Special Issue will include original articles and reviews that investigate signaling pathways of resistance to immunotherapy and new therapeutic strategies for lung cancer. We encourage contributions that explore the cellular and molecular aspects of resistance or recent advances including adoptive cell therapy and therapeutic cancer vaccines. Preclinical and clinical studies investigating the impact of the tumor microenvironment on the immunological response are also warranted.

Dr. Elizabeth Fabre
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy resistance
  • biomarkers
  • adoptive cell therapy
  • cancer vaccines
  • lung cancer

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 2691 KiB  
Article
Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling—New Cues on CAT-VTE
by Catarina Freitas-Dias, Filipe Gonçalves, Filipa Martins, Isabel Lemos, Luís G. Gonçalves and Jacinta Serpa
Cells 2024, 13(4), 305; https://doi.org/10.3390/cells13040305 - 7 Feb 2024
Cited by 2 | Viewed by 1453
Abstract
Background: Cancer-associated thrombosis (CAT) and venous thromboembolism (VTE) are frequent cancer-related complications associated with high mortality; thus, this urges the identification of predictive markers. Immune checkpoint inhibitors (ICIs) used in cancer immunotherapy allow T-cell activation against cancer cells. Retrospective studies showed increased VTE [...] Read more.
Background: Cancer-associated thrombosis (CAT) and venous thromboembolism (VTE) are frequent cancer-related complications associated with high mortality; thus, this urges the identification of predictive markers. Immune checkpoint inhibitors (ICIs) used in cancer immunotherapy allow T-cell activation against cancer cells. Retrospective studies showed increased VTE following ICI administration in some patients. Non-small cell lung cancer (NSCLC) patients are at high risk of thrombosis and thus, the adoption of immunotherapy, as a first-line treatment, seems to be associated with coagulation-fibrinolysis derangement. Methods: We pharmacologically modulated NSCLC cell lines in co-culture with CD8+ T-cells (TCD8+) and myeloid-derived suppressor cells (MDSCs), isolated from healthy blood donors. The effects of ICIs Nivolumab and Ipilimumab on NSCLC cell death were assessed by annexin V and propidium iodide (PI) flow cytometry analysis. The potential procoagulant properties were analyzed by in vitro clotting assays and enzyme-linked immunosorbent assays (ELISAs). The metabolic remodeling induced by the ICIs was explored by 1H nuclear magnetic resonance (NMR) spectroscopy. Results: Flow cytometry analysis showed that TCD8+ and ICIs increase cell death in H292 and PC-9 cells but not in A549 cells. Conditioned media from NSCLC cells exposed to TCD8+ and ICI induced in vitro platelet aggregation. In A549, Podoplanin (PDPN) levels increased with Nivolumab. In H292, ICIs increased PDPN levels in the absence of TCD8+. In PC-9, Ipilimumab decreased PDPN levels, this effect being rescued by TCD8+. MDSCs did not interfere with the effect of TCD8+ in the production of TF or PDPN in any NSCLC cell lines. The exometabolome showed a metabolic remodeling in NSCLC cells upon exposure to TCD8+ and ICIs. Conclusions: This study provides some insights into the interplay of immune cells, ICIs and cancer cells influencing the coagulation status. ICIs are important promoters of coagulation, benefiting from TCD8+ mediation. The exometabolome analysis highlighted the relevance of acetate, pyruvate, glycine, glutamine, valine, leucine and isoleucine as biomarkers. Further investigation is needed to validate this finding in a cohort of NSCLC patients. Full article
(This article belongs to the Special Issue State of the Art and Perspectives in Lung Cancer Immunotherapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop